Trials / Completed
CompletedNCT00251199
VX-950 and Peginterferon for Hepatitis C
A Phase 1b Viral Kinetic Study of VX-950 and Peginterferon in Hepatitis C
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- —
Summary
VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-950 | |
| DRUG | peginterferon |
Timeline
- Start date
- 2005-10-01
- Completion
- 2006-03-01
- First posted
- 2005-11-09
- Last updated
- 2007-12-21
Locations
2 sites across 2 countries: Germany, Netherlands
Source: ClinicalTrials.gov record NCT00251199. Inclusion in this directory is not an endorsement.